SCHEMBL2256282

SCHEMBL2256282

O=C(COc1cc(C(F)(F)F)nn1-c1ccccc1Cl)NCCc1ccc(Cl)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.49
▸ PTPRC P08575 1/20 0.48
▸ PTPN1 P18031 1/20 0.48
▸ PTPN11 Q06124 1/20 0.48
▸ PTPN13 Q12923 1/20 0.48
▸ PTPN22 Q9Y2R2 1/20 0.48
▸ HPGD P15428 1/20 0.46
▸ CNR1 P21554 2/20 0.45
▸ TRPV1 Q8NER1 4/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2255354 0.93 TRPV1 (0.46) LMNAPTPRCPTPN1PTPN11PTPN13
SCHEMBL2260645 0.91 TRPV1 (0.49) LMNACNR1TRPV1SMN1; SMN2
SCHEMBL2256123 0.89 TRPV1 (0.44) LMNACNR1TRPV1ALDH1A1KDM4E
SCHEMBL2257541 0.88 TRPV1 (0.46) LMNAPTPRCPTPN1PTPN11PTPN13
SCHEMBL2256384 0.88 TRPV1 (0.42) LMNATRPV1ALDH1A1MAPTSMN1; SMN2
SCHEMBL2255860 0.88 TGFBR1 (0.42) LMNATRPV1ALDH1A1MAPTTP53
SCHEMBL2258277 0.87 GLA (0.48) LMNACNR1TRPV1ALDH1A1KDM4E
SCHEMBL2259409 0.87 TGFBR1 (0.41) LMNAPTPRCPTPN1PTPN11PTPN13
SCHEMBL2263175 0.86 ALDH1A1 (0.46) LMNAHPGDALDH1A1MEN1KMT2A
SCHEMBL2257432 0.86 TRPV1 (0.48) CNR1TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121621-B1 LXR AND FXR MODULATORS EXELIXIS PATENT CO LLC (US) 2014-05-07 — — EP disclosed
US-7998995-B2 LXR and FXR modulators EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 — — US disclosed
US-7998995-B2 LXR and FXR modulators EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 — — US disclosed
US-7998995-B2 LXR and FXR modulators EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 — — US disclosed
US-20100069367-A1 LXR and FXR Modulators EXELIXIS, INC. (US) 2010-03-18 — — US disclosed
US-20100069367-A1 LXR and FXR Modulators EXELIXIS, INC. (US) 2010-03-18 — — US disclosed
US-20100069367-A1 LXR and FXR Modulators EXELIXIS, INC. (US) 2010-03-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069367-A1 LXR and FXR Modulators NR1H3, NR1H2, NR1H4 LMNA 2267/4885PTPRC 3701/4885PTPN1 1346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback